OZSC stock is publicly traded on the OTC Markets under the ticker symbol “OZSC”. OZSC is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for severe and life-threatening diseases. Their lead product candidate, THR-18, is a novel, first-in-class monoclonal antibody targeting the CD26 receptor, which is implicated in various cancers and immune disorders.
The company has been recognized for its promising pipeline and strong scientific team, including its collaboration with the National Cancer Institute. As of 2023, OZSC stock has demonstrated significant growth potential, attracting interest from investors and analysts alike. Its strategic partnerships, such as the licensing agreement with Aurigene Discovery Technologies, further enhance its position in the biopharmaceutical industry.
